European Patent Office Backs AstraZeneca's Symbicort Patent
As a result, no generic manufacturer can launch an equivalent product until AstraZeneca’s data exclusivity has expired or the generic company has submitted its own regulatory package, utilizing its own clinical data.
Astrazeneca has data protection for the drug in most major European until 2010. The European combination patent expires in 2012 with extension by supplementary...
To view the full article, register now.